Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma : Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
© 2022 John Wiley & Sons Ltd..
The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM). The present study is a 3-year follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloRd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow-up of 36 months (range 6-55), 236 patients experienced disease progression or died. Median progression-free survival (PFS) and overall survival (OS) were 18.4 and 34 months, respectively. The updated multivariate analyses showed a significant reduction of PFS and OS benefit magnitude only in cases with International Staging System stage III. Major adverse events included grade 3/4 neutropenia (18.5%), anemia (15.4%), lymphocytopenia (12.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 33.9% and 18.9%, respectively. No new safety signals with longer follow-up have been observed. Of 319 patients, 245 (76.7%) reached at least a partial remission. A significantly lower response rate was found in patients previously exposed to lenalidomide. In conclusion, our study confirms that EloRd is a safe and effective regimen for RRMM patients, maintaining benefits across multiple unfavorable subgroups.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Hematological oncology - 40(2022), 4 vom: 24. Okt., Seite 704-715 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
1351PE5UGS |
|---|
| Anmerkungen: |
Date Completed 07.10.2022 Date Revised 11.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/hon.3031 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341306533 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341306533 | ||
| 003 | DE-627 | ||
| 005 | 20231226011455.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hon.3031 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1137.xml |
| 035 | |a (DE-627)NLM341306533 | ||
| 035 | |a (NLM)35608183 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bruzzese, Antonella |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma |b Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.10.2022 | ||
| 500 | |a Date Revised 11.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons Ltd. | ||
| 520 | |a The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM). The present study is a 3-year follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloRd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow-up of 36 months (range 6-55), 236 patients experienced disease progression or died. Median progression-free survival (PFS) and overall survival (OS) were 18.4 and 34 months, respectively. The updated multivariate analyses showed a significant reduction of PFS and OS benefit magnitude only in cases with International Staging System stage III. Major adverse events included grade 3/4 neutropenia (18.5%), anemia (15.4%), lymphocytopenia (12.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 33.9% and 18.9%, respectively. No new safety signals with longer follow-up have been observed. Of 319 patients, 245 (76.7%) reached at least a partial remission. A significantly lower response rate was found in patients previously exposed to lenalidomide. In conclusion, our study confirms that EloRd is a safe and effective regimen for RRMM patients, maintaining benefits across multiple unfavorable subgroups | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a dexamethasone | |
| 650 | 4 | |a elotuzumab | |
| 650 | 4 | |a lenalidomide | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a salvage therapy | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a elotuzumab |2 NLM | |
| 650 | 7 | |a 1351PE5UGS |2 NLM | |
| 650 | 7 | |a Thalidomide |2 NLM | |
| 650 | 7 | |a 4Z8R6ORS6L |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Lenalidomide |2 NLM | |
| 650 | 7 | |a F0P408N6V4 |2 NLM | |
| 700 | 1 | |a Derudas, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Galli, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Martino, Enrica Antonia |e verfasserin |4 aut | |
| 700 | 1 | |a Rocco, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Conticello, Concetta |e verfasserin |4 aut | |
| 700 | 1 | |a Califano, Catello |e verfasserin |4 aut | |
| 700 | 1 | |a Giuliani, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Mangiacavalli, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Farina, Giuliana |e verfasserin |4 aut | |
| 700 | 1 | |a Lombardo, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Brunori, Marino |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Antonioli, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Ria, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Zambello, Renato |e verfasserin |4 aut | |
| 700 | 1 | |a Di Renzo, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Mele, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Marcacci, Gianpaolo |e verfasserin |4 aut | |
| 700 | 1 | |a Pietrantuono, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Palumbo, Gaetano |e verfasserin |4 aut | |
| 700 | 1 | |a Cascavilla, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Cerchione, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Belotti, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Criscuolo, Clelia |e verfasserin |4 aut | |
| 700 | 1 | |a Uccello, Giuseppina |e verfasserin |4 aut | |
| 700 | 1 | |a Curci, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Vigna, Ernesto |e verfasserin |4 aut | |
| 700 | 1 | |a Mendicino, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Iaccino, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Mimmi, Selena |e verfasserin |4 aut | |
| 700 | 1 | |a Botta, Cirino |e verfasserin |4 aut | |
| 700 | 1 | |a Vincelli, Donatella |e verfasserin |4 aut | |
| 700 | 1 | |a Sgherza, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Bonalumi, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Cupelli, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Stocchi, Raffaella |e verfasserin |4 aut | |
| 700 | 1 | |a Martino, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Ballanti, Stelvio |e verfasserin |4 aut | |
| 700 | 1 | |a Gangemi, Dominella |e verfasserin |4 aut | |
| 700 | 1 | |a Gagliardi, Alfredo |e verfasserin |4 aut | |
| 700 | 1 | |a Gamberi, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Pompa, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Tripepi, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Frigeri, Ferdinando |e verfasserin |4 aut | |
| 700 | 1 | |a Consoli, Ugo |e verfasserin |4 aut | |
| 700 | 1 | |a Bringhen, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Zamagni, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Patriarca, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a De Stefano, Valerio |e verfasserin |4 aut | |
| 700 | 1 | |a Di Raimondo, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Palmieri, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Petrucci, Maria Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Offidani, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Musto, Pellegrino |e verfasserin |4 aut | |
| 700 | 1 | |a Boccadoro, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Cavo, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Neri, Antonino |e verfasserin |4 aut | |
| 700 | 1 | |a Morabito, Fortunato |e verfasserin |4 aut | |
| 700 | 1 | |a Gentile, Massimo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hematological oncology |d 1993 |g 40(2022), 4 vom: 24. Okt., Seite 704-715 |w (DE-627)NLM012648280 |x 1099-1069 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2022 |g number:4 |g day:24 |g month:10 |g pages:704-715 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/hon.3031 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2022 |e 4 |b 24 |c 10 |h 704-715 | ||